BRIP1 germline pathogenic and breast cancer: weak/uncertain risk association (NCCN does n...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRIP1-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRIP1 germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IIIA |
| Recommended combinations | standard breast therapy by subtype |
| Evidence summary | BRIP1 germline pathogenic and breast cancer: weak/uncertain risk association (NCCN does not currently recommend enhanced breast surveillance based on BRIP1 alone). No PARPi indication. ESCAT IIIA / OncoKB Level 3B. |
Notes
Cascade testing for ovarian risk (the better-established BRIP1 association).
Used By
No reverse references found in the YAML corpus.